{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:39:11Z","timestamp":1778852351853,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing medical scientific research project","award":["No. 2024MSXM023"],"award-info":[{"award-number":["No. 2024MSXM023"]}]},{"name":"the Yongchuan Hospital of Chongqing Medical University Research Project","award":["No. YJJL2024083"],"award-info":[{"award-number":["No. YJJL2024083"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04166-1","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:38:10Z","timestamp":1760078290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Ning","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"4166_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A et al (2023) Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III poseidon study. JCO 41:1213\u20131227","journal-title":"JCO"},{"key":"4166_CR2","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060","journal-title":"Curr Oncol"},{"key":"4166_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C (2022) Non-small cell lung cancer in China. Cancer Commun 42:937\u2013970","journal-title":"Cancer Commun"},{"key":"4166_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMoa2212083","volume":"388","author":"N Altorki","year":"2023","unstructured":"Altorki N, Wang X, Kozono D et al (2023) Lobar or sublobar resection for peripheral stage IA non\u2013small-cell lung cancer. N Engl J Med 388:489\u2013498","journal-title":"N Engl J Med"},{"key":"4166_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I et al (2021) Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol 7:1824","journal-title":"JAMA Oncol"},{"key":"4166_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non\u2013small-cell lung cancer. JCO 40:586\u2013597","journal-title":"JCO"},{"key":"4166_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","volume":"11","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H et al (2022) Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells 11:320","journal-title":"Cells"},{"key":"4166_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/diagnostics13061041","volume":"13","author":"BP Sorroche","year":"2023","unstructured":"Sorroche BP, Teixeira RdeJ, Pereira CAD et al (2023) PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors\u2019 response and survival in advanced melanoma patients in Brazil. Diagnostics 13:1041","journal-title":"Diagnostics"},{"key":"4166_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-02985-1","author":"X Tu","year":"2024","unstructured":"Tu X, Chen L, Zheng Y et al (2024) S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-024-02985-1","journal-title":"J Exp Clin Cancer Res"},{"key":"4166_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang Z, Liu X, Zhu J et al (2025) Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell 43:86-102.e10","journal-title":"Cancer Cell"},{"key":"4166_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02001-7","author":"W Zhang","year":"2024","unstructured":"Zhang W, Qin H, Wang G et al (2024) Deciphering the potential role of PGRN in regulating CD8+ T cell antitumor immunity. Cell Death Discov. https:\/\/doi.org\/10.1038\/s41420-024-02001-7","journal-title":"Cell Death Discov"},{"key":"4166_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ydbio.2024.02.002","volume":"509","author":"L Yang","year":"2024","unstructured":"Yang L, Liao J, Huang H et al (2024) Stage-specific regulation of undifferentiated spermatogonia by AKT1S1-mediated AKT-mTORC1 signaling during mouse spermatogenesis. Dev Biol 509:11\u201327","journal-title":"Dev Biol"},{"key":"4166_CR13","doi-asserted-by":"publisher","first-page":"37S","DOI":"10.1177\/0963689719890860","volume":"28","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wei P, Lv W et al (2019) MELK is upregulated in advanced clear cell renal cell carcinoma and promotes disease progression by phosphorylating PRAS40. Cell Transplant 28:37S-50S","journal-title":"Cell Transplant"},{"key":"4166_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04499-0","author":"T Zhang","year":"2022","unstructured":"Zhang T, Wang Y, Yu H et al (2022) PGK1 represses autophagy-mediated cell death to promote the proliferation of liver cancer cells by phosphorylating PRAS40. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-022-04499-0","journal-title":"Cell Death Dis"},{"key":"4166_CR15","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/cas.15432","volume":"113","author":"W Shen","year":"2022","unstructured":"Shen W, Du W, Li Y et al (2022) Tifa promotes colorectal cancer cell proliferation in an RSK- and PRAS40-dependent manner. Cancer Sci 113:3018\u20133031","journal-title":"Cancer Sci"},{"key":"4166_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/1061186X.2021.1882470","volume":"29","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Tang S, Zhang X, Chen L (2021) Targeting PRAS40: a novel therapeutic strategy for human diseases. J Drug Target 29:703\u2013715","journal-title":"J Drug Target"},{"key":"4166_CR17","doi-asserted-by":"publisher","first-page":"565669","DOI":"10.3389\/fonc.2020.565669","volume":"10","author":"G Chen","year":"2021","unstructured":"Chen G, Li Z, Chen C et al (2021) The molecular landscape and biological alterations induced by PRAS40-knockout in head and neck squamous cell carcinoma. Front Oncol 10:565669","journal-title":"Front Oncol"},{"key":"4166_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bcp.2019.05.014","volume":"166","author":"N Van Der Steen","year":"2019","unstructured":"Van Der Steen N, Leonetti A, Keller K et al (2019) Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Biochem Pharmacol 166:128\u2013138","journal-title":"Biochem Pharmacol"},{"key":"4166_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M et al (2020) Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med 26:688\u2013692","journal-title":"Nat Med"},{"key":"4166_CR20","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.3390\/cells12152014","volume":"12","author":"AN Gargalionis","year":"2023","unstructured":"Gargalionis AN, Papavassiliou KA, Papavassiliou AG (2023) Implication of mTOR signaling in NSCLC: mechanisms and therapeutic perspectives. Cells 12:2014","journal-title":"Cells"},{"key":"4166_CR21","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1158\/1541-7786.MCR-19-0592","volume":"18","author":"MI Dougherty","year":"2020","unstructured":"Dougherty MI, Lehman CE, Spencer A et al (2020) PRAS40 phosphorylation correlates with Insulin-Like Growth Factor-1 Receptor-induced resistance to epidermal growth factor receptor inhibition in head and neck cancer cells. Mol Cancer Res 18:1392\u20131401","journal-title":"Mol Cancer Res"},{"key":"4166_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature25023","volume":"552","author":"H Yang","year":"2017","unstructured":"Yang H, Jiang X, Li B et al (2017) Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature 552:368\u2013373","journal-title":"Nature"},{"key":"4166_CR23","doi-asserted-by":"publisher","first-page":"155946","DOI":"10.1016\/j.phymed.2024.155946","volume":"134","author":"L Cheng","year":"2024","unstructured":"Cheng L, Xiang S, Yu Q et al (2024) Paeoniflorin inhibits PRAS40 interaction with Raptor to activate mTORC1 to reverse excessive autophagy in airway epithelial cells for asthma. Phytomedicine 134:155946","journal-title":"Phytomedicine"},{"key":"4166_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41388-020-01558-8","volume":"40","author":"L Yao","year":"2020","unstructured":"Yao L, Xuan Y, Zhang H et al (2020) Reciprocal REG\u03b3-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma. Oncogene 40:677\u2013692","journal-title":"Oncogene"},{"key":"4166_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.drudis.2016.04.005","volume":"21","author":"ZZ Chong","year":"2016","unstructured":"Chong ZZ (2016) Targeting PRAS40 for multiple diseases. Drug Discov Today 21:1222\u20131231","journal-title":"Drug Discov Today"},{"key":"4166_CR26","doi-asserted-by":"publisher","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","volume":"9","author":"MV Negrao","year":"2021","unstructured":"Negrao MV, Skoulidis F, Montesion M et al (2021) Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9:e002891","journal-title":"J Immunother Cancer"},{"key":"4166_CR27","first-page":"33","volume":"1","author":"DH Josephs","year":"2015","unstructured":"Josephs DH, Sarker D (2015) pharmacodynamic biomarker development for PI3K pathway therapeutics. Transl Oncogenom Suppl 1:33\u201349","journal-title":"Transl Oncogenom Suppl"},{"key":"4166_CR28","doi-asserted-by":"publisher","first-page":"e0183048","DOI":"10.1371\/journal.pone.0183048","volume":"12","author":"J Maynard","year":"2017","unstructured":"Maynard J, Emmas S-A, Ble F-X et al (2017) The use of 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3K\u03b1 inhibitor. PLoS ONE 12:e0183048","journal-title":"PLoS ONE"},{"key":"4166_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211036814","author":"T Cholewinski","year":"2021","unstructured":"Cholewinski T, Pereira D, Moerland M, Jacobs GE (2021) MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants. Ther Adv Psychopharmacol. https:\/\/doi.org\/10.1177\/20451253211036814","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04166-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T17:20:13Z","timestamp":1763054413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04166-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4166"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04166-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Clinical Ethics Committee of Yongchuan hospital of Chongqing Medical University (No.2023-KeLunShen-106).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"335"}}